Savara (NASDAQ:SVRA) Shares Gap Down on Analyst Downgrade

Shares of Savara Inc (NASDAQ:SVRA) gapped down before the market opened on Wednesday after HC Wainwright lowered their price target on the stock from $10.00 to $6.00. The stock had previously closed at $3.83, but opened at $3.67. HC Wainwright currently has a buy rating on the stock. Savara shares last traded at $3.61, with a volume of 493,595 shares traded.

Several other analysts have also recently commented on SVRA. JMP Securities restated a “market outperform” rating and set a $9.00 price target on shares of Savara in a report on Tuesday, October 1st. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 price objective (down previously from $7.00) on shares of Savara in a research report on Wednesday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.17.

Hedge Funds Weigh In On Savara

Institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets boosted its stake in Savara by 92.3% during the first quarter. BNP Paribas Financial Markets now owns 73,494 shares of the company’s stock worth $366,000 after buying an additional 35,269 shares in the last quarter. Swiss National Bank acquired a new stake in shares of Savara in the 1st quarter valued at $732,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Savara in the 1st quarter valued at $394,000. ProShare Advisors LLC boosted its stake in shares of Savara by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock valued at $128,000 after purchasing an additional 2,114 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Savara by 2.5% in the first quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock valued at $30,197,000 after buying an additional 148,673 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Price Performance

The stock has a fifty day moving average of $3.97 and a 200-day moving average of $4.22. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $584.33 million, a P/E ratio of -8.45 and a beta of 1.02.

Savara (NASDAQ:SVRA) last released its earnings results on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Equities analysts predict that Savara Inc will post -0.44 EPS for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.